What's Happening?
Poxel, a biopharmaceutical company listed on Euronext Paris, has announced the appointment of Yves Decadt as its new Chief Executive Officer, effective June 10, 2026. Decadt succeeds Nicolas Trouche, who played a pivotal role during the company's restructuring
phase that began in August 2025. The transition aligns with Poxel's strategic plan to enhance its portfolio development and forge strategic partnerships. Decadt, who has been a board member since October 2025, brings over 25 years of experience in the pharmaceutical industry, including significant roles at Johnson & Johnson. His immediate focus will be on accelerating partnerships for the commercialization of Imeglimin outside Japan, particularly targeting China and other Asian markets, and advancing the development of PXL065 for treating hypertrophic cardiomyopathy and metabolic dysfunction-associated steatohepatitis.
Why It's Important?
The appointment of Yves Decadt as CEO is a strategic move for Poxel as it seeks to expand its market presence and enhance its product offerings. Decadt's extensive experience in international business development, particularly in Asia, positions him well to lead Poxel's efforts in securing strategic partnerships that are crucial for the company's growth. The focus on Imeglimin, already successful in Japan, and PXL065, highlights Poxel's commitment to addressing significant health challenges such as type 2 diabetes and cardiomyopathy. This leadership change is expected to drive Poxel's commercial ambitions and create value for stakeholders, including shareholders and patients, by leveraging Decadt's expertise and network.
What's Next?
Under Yves Decadt's leadership, Poxel is expected to intensify its efforts in forming strategic alliances, particularly in the Asian markets, to commercialize its key products. The company will likely focus on executing its Continuation Plan, approved by the Lyon Commercial Court, to ensure business continuity and growth. Stakeholders, including shareholders and partners, will be closely monitoring the company's progress in securing partnerships and advancing its product pipeline. The successful implementation of these strategies could significantly enhance Poxel's market position and financial performance.
